Xiaohong Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaohong Zhang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Bing Wu
Department of Geriatrics, The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou 730050, China
1 shared publicationHantao Mu
Department of Gastroenterology, Chengdu East New Area Second People's Hospital, Chengdu 641421, China
1 shared publication- Hong Yang
Department of Obstetrics and Gynecology, Xijing Hospital, The Fourth Military Medical University, China
1 shared publication - Hulin Chang
Department of Hepatobiliary Surgery, Shaanxi Provincial People's Hospital, Xi'an 710068, China
1 shared publication Jianhua Yuan
Department of Gastroenterology, Chengdu East New Area Second People's Hospital, Chengdu 641421, China
1 shared publicationJie He
Department of Gastroenterology, Chengdu East New Area Second People's Hospital, Chengdu 641421, China
1 shared publication
Latest Publications
- 24 May 2026
- Published by Elsevier in Pathology - Research and Practice
- Vol. 285, 156561
Upregulation of TWNK promotes proliferation and invasion of liver cancer by enhancing mitochondrial respiration
- 24 May 2026
- Published by Elsevier in Pathology - Research and Practice
- Vol. 285, 156561
Upregulation of TWNK promotes proliferation and invasion of liver cancer by enhancing mitochondrial respiration
- Open Access
- 19 January 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-14
CRAT downregulation promotes ovarian cancer progression by facilitating mitochondrial metabolism through decreasing the acetylation of PGC-1α
Mitochondrial dysfunctions are closely associated with different types of disease, including cancer. Carnitine acetyltransferase (CRAT) is a mitochondrial-localized enzyme catalyzing the reversible transfer of acyl groups from an acyl-CoA thioester to carnitine and regulates the ratio of acyl-CoA/CoA. Our bioinformatics analysis using public database revealed a significant decrease of CRAT expression in ovarian cancer (OC). However, the functions of CRAT have rarely been investigated in human cancers, especially in OC. Here, we found a frequent down-regulation of CRAT in OC, which is mainly caused by up-regulation of miR-132-5p. Downregulation of CRAT was significantly associated with shorter survival time for patients with OC. Forced expression of CRAT suppressed OC growth and metastasis by inducing cell cycle arrest and epithelial to mesenchymal transition (EMT). By contrast, CRAT knockdown promoted OC growth and metastasis. Mechanistically, we found that CRAT downregulation promoted OC growth and metastasis by increasing mitochondrial biogenesis to facilitate mitochondrial metabolism through reducing the acetylation of peroxisome proliferator-activated receptor-γ coactivator (PGC-1α). In summary, CRAT functions as a critical tumor suppressor in OC progression by enhancing PGC-1α-mediated mitochondrial biogenesis and metabolism, suggesting CRAT as a potential therapeutic target in treatment of OC.
- 19 January 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-14
Open AccessCRAT downregulation promotes ovarian cancer progression by facilitating mitochondrial metabolism through decreasing the acetylation of PGC-1α
Mitochondrial dysfunctions are closely associated with different types of disease, including cancer. Carnitine acetyltransferase (CRAT) is a mitochondrial-localized enzyme catalyzing the reversible transfer of acyl groups from an acyl-CoA thioester to carnitine and regulates the ratio of acyl-CoA/CoA. Our bioinformatics analysis using public database revealed a significant decrease of CRAT expression in ovarian cancer (OC). However, the functions of CRAT have rarely been investigated in human cancers, especially in OC. Here, we found a frequent down-regulation of CRAT in OC, which is mainly caused by up-regulation of miR-132-5p. Downregulation of CRAT was significantly associated with shorter survival time for patients with OC. Forced expression of CRAT suppressed OC growth and metastasis by inducing cell cycle arrest and epithelial to mesenchymal transition (EMT). By contrast, CRAT knockdown promoted OC growth and metastasis. Mechanistically, we found that CRAT downregulation promoted OC growth and metastasis by increasing mitochondrial biogenesis to facilitate mitochondrial metabolism through reducing the acetylation of peroxisome proliferator-activated receptor-γ coactivator (PGC-1α). In summary, CRAT functions as a critical tumor suppressor in OC progression by enhancing PGC-1α-mediated mitochondrial biogenesis and metabolism, suggesting CRAT as a potential therapeutic target in treatment of OC.